CpG 1018

GPTKB entity

Statements (22)
Predicate Object
gptkbp:instanceOf vaccine
gptkbp:approvedBy gptkb:FDA
hepatitis B vaccine
gptkbp:CASNumber 1413969-25-3
gptkbp:clinicalTrialPhase phase 3
gptkbp:composition 22-mer oligonucleotide
gptkbp:contains unmethylated CpG motifs
synthetic oligodeoxynucleotide
gptkbp:developedBy gptkb:Dynavax_Technologies
gptkbp:effect enhances immune response
induces Th1-biased immune response
https://www.w3.org/2000/01/rdf-schema#label CpG 1018
gptkbp:mechanismOfAction TLR9 agonist
gptkbp:routeOfAdministration intramuscular
gptkbp:target human TLR9
gptkbp:usedIn COVID-19 vaccine candidates
VLA2001
HEPLISAV-B
SCB-2019 vaccine
adjuvanted protein subunit vaccines
gptkbp:bfsParent gptkb:MVC-COV1901
gptkbp:bfsLayer 8